

P20938.201

UTILITY  
PATENT APPLICATION  
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

P20938

Total Pages

Inventor(s) or Applicant(s) Identifier  
Kiyoshi NAKAYAMA, Masami OHTSUKA, Haruko  
KAWATO, William WATKINS, Jason ZHANG, Monica  
PALME, and Aesop CHO

Title: DRUG EFFLUX PULP INHIBITOR

ADDRESS TO:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

## APPLICATION ELEMENTS

## ACCOMPANYING APPLICATION PARTS

1. ☒ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
  - a. ☐ Small Entity Statement(s)
3. ☒ Specification (in Japanese) [Total Pages 216 ]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- ☐ Drawing(s) (35 USC 113) [Total Sheets      ]
- ☒ Oath or Declaration [Total Pages 5 ]
  - a. ☐ Newly executed (original or copy) ☒ Unexecuted
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 20 completed)  
[Note Box 6 below]
    - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s)  
named in the prior application, see 37 CFR  
1.63(d)(2) and 1.33(b).
- ☐ Incorporation By Reference (useable if Box 5b is checked)  
The entire disclosure of the prior application, from which a  
copy of the oath or declaration is supplied under Box 5b, is  
considered as being part of the disclosure of the accompanying  
application and is hereby incorporated by reference therein.
- ☐ Application Data Sheet. See 37 CFR 1.76
- ☐ CD-Rom or CD-R in duplicate, large table or Computer  
Program (Appendix)

9. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ paper
  - c. ☐ Statements verifying identity of above copies
10. ☐ Assignment Papers (cover sheet & document(s))
11. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
12. ☐ English Translation Document (if applicable)
13. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
14. ☐ Preliminary Amendment
15. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
16. ☐ Figure of Drawing to be published
17. ☐ Foreign priority claimed
  - a. ☐ Claim of Priority
  - b. ☐ Certified Copy of Priority Document(s)
18. ☒ Assignee: DAIICHI PHARMACEUTICAL CO., LTD. of  
Tokyo, JAPAN, and MICROCID  
PHARMACEUTICALS, INC. of Mountain View, California
19. ☒ Other: Cover Letter under 37 CFR 1.53(b) and (f) and  
MPEP 608.01

20. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior Application No.          /         , filed           
 Prior application information: Examiner:                      Group Art Unit:                     

 21. ☐ Amend the specification by inserting before the first line the sentence;  
 This application is a      continuation-in-part,      continuation,      divisional, of Application No.          /         , filed         
Address all future correspondence to **Customer No. 7055** at the present address of:
 GREENBLUM & BERNSTEIN, P.L.C.  
 1941 Roland Clarke Place  
 Reston, VA 20191  
 (703) 716-1191

Date

 Signature  
 Bruce H. Bernstein, Reg No. 29,027  
 Typed or Printed Name

## FEE TRANSMITTAL

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Concurrently Herewith
First Named Inventor	K. NAKAYAMA et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned

TOTAL AMOUNT OF PAYMENT (\$)710.00

Attorney Docket Number P20938

## METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 19-0089Deposit Account Name GREENBLUM & BERNSTEIN, P.L.C.

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17, including any required extension of time fees in any concurrent or future

reply requiring a petition for extension of time for its timely submission (37 CFR 1.136(a)(3))

- ☐ Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)

- ☐ Applicant Claims Small Entity Status See 37 CFR 1.27.

2. ☒ Payment Enclosed:

☒ Check ☐ Credit Card ☐ Money Order ☐ Other

## FEE CALCULATION (fees effective 12/29/99)

## 1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	<u>710</u>
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$) 710

## 2. CLAIMS

Total Claims	Extra	Fee from below	Fee Paid
Independent -20=	x	18	
Claims -3=	x	80	
Multiple Dependent Claims	x		<u>0</u>

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim
109	80	209	40	Reissue independent claims over original patent
110	18	210	9	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

## FEE CALCULATION (continued)

## 3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR	
113	1,840*	113	1,840*	Prior to Examiner action	
				Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for response within 1st month	
116	390	216	195	Extension for response within 2nd month	
117	890	217	445	Extension for response within 3rd month	
118	1,390	218	695	Extension for response within 4th month	
128	1,890	228	945	Extension for response within 5th month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive unavoidably abandoned application	
141	1,240	241	620	Petition to revive unintentionally abandoned application	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of IDS	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

Other fee (specify) \_\_\_\_\_

SUBTOTAL (3) (\$) 0.00

\*Reduced by Basic Filing Fee paid

## SUBMITTED BY

Complete (if applicable)

Typed or Printed Name Bruce H. Bernstein

Reg. Number

29,027

Signature

Leslie M. Pappas Reg. No.

Date

4/26/01

Deposit Account User ID

P20938.P03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :K. NAKAYAMA et al.

Serial No :Not Yet Assigned

Filed :Concurrently herewith

For :DRUG EFFLUX PUMP INHIBITOR

**COVER LETTER ACCOMPANYING U.S. PATENT APPLICATION  
FILED UNDER 37 C.F.R. 1.53(b) AND 1.53(f) AND M.P.E.P. 608.01**

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Enclosed is a new patent application for filing in the U.S. Patent and Trademark Office under 37 C.F.R. 1.53(b) and (f) and M.P.E.P. 608.01. The Declaration and Power of Attorney attached hereto is in unexecuted form and the application is in the Japanese language. An executed Declaration and Power of Attorney and verified literal English translation will be filed within the time period set forth in the Notice to File Missing Parts of Application, unless such time period has been extended by the filing of a petition accompanied by the extension fee under the provisions of 37 C.F.R. 1.136(a).

P20938.P03


Related to this, a correspondence address is provided in the unexecuted Declaration and Power of Attorney, and is as follows:

GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191

The above-identified application includes:

- 216 pages of specification with abstract(in Japanese); and
- an unexecuted Declaration and Power of Attorney.

Respectfully submitted,  
K. NAKAYAMA et al.

  
Bruce H. Bernstein  
Reg. No. 29,027 33,329

April 23, 2001  
GREENBLUM & BERNSTEIN P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

094224-0460  
FO9240-4E224860